EnGeneIC Limited today announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGeneIC Dream Vector) therapy in patients with ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to WP1122 for the treatment of glioblastoma multiforme, according to a ...
Ottawa, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The global glioblastoma multiforme treatment market size is predicted to increase from USD 3.01 billion in 2025 to approximately USD 5.68 billion by 2033, ...
Glioblastoma multiforme (GBM) is the most common and aggressive type of tumor arising from star shaped cells called as astrocytes that make up supportive tissue of the brain. GBM has long baffled ...
Gleolan, a dye used for brain imaging, can help surgeons visualize tumor tissue during surgery for glioblastoma multiforme. Malignant transformation occurs from aggregation of genetic alterations and ...
Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The global Glioblastoma Multiforme (GBM) ...
Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM) ...
Glioblastoma multiforme is the most common malignant primary brain tumor in adults. Mean progression-free survival is just over 6 months; treatment with surgical resection, chemotherapy, and radiation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results